(Reuters) -Metsera, an obesity drug developer, said on Friday that it has entered into an amended merger agreement with Pfizer, in which the New York-based company will acquire Metsera for up to $86.25 per share. Metsera's board has recommended that its shareholders "approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer." (Reporting by Rishabh Jaiswal in Bengaluru; Editing by Leslie Adler and Thomas Derpinghaus)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Hyunjoo Jin SEOUL, Jan 1 (Reuters) - The U.S. government has granted an annual…
VIDEO SHOWS: IOC PRESIDENT KIRSTY COVENTRY SPEAKING RESENDING WITH FULL SCRIPT SHOWS: LAUSANNE, SWITZERLAND (RECENT)…
VIDEO SHOWS: FILE FOOTAGE OF PAT CUMMINS AND AUSTRALIAN CRICKET TEAM PRACTISING SHOWS: COMPLETE SHOTLIST…
VIDEO SHOWS: POST-MATCH COMMENTS FROM IVORY COAST COACH EMERSE FAE FOLLOWING HIS SIDE'S 3-2 WIN…
SEOUL, Jan 1 (Reuters) - The U.S. government has granted an annual license to Taiwan…
VIDEO SHOWS: SAUDI PRO LEAGUE HIGHLIGHTS WITH AL HILAL WINNING 3-1 AT AL KHOLOOD SHOWS:…